Figure 4
IDX combined with cis induces
T cells migration towards tumor cells via CXCL10/type I IFN axis
(A) CD45+ for total leukocytes migrate towards C17 and
NPC43+ve tumor cell lines following IDX and cis treatments alone or
combined were measured in flow cytometry. (B) Specific migratory effects
of the % CD3 T cells/CD45 cells, ** p<0.01 when compared to
control (DMSO). (C) % CD4 helper T cells/CD3 cells, (D) % CD8
cytotoxic T cells/CD3 cells and (E) % double positive CD4 CD8 cells/CD3
cells (E) relative control (DMSO) were quantified. * p≤0.05 when
compared to control (DMSO). (F) Tumor cells were pre-treated with
brefeldin A (5 µg/mL) followed by treatment with the drugs
alone/combined at the indicated concentrations for 8 hours Western blots
were performed on the cell lysates with the indicated antibodies. p-IRF
(396) and p-IRF (386) indicate phosphorylated serine 396 and 386,
respectively. (G) Antibody array analysis of inflammatory cytokines in
conditioned media from indicated NPC cell line following treatment with
IDX, cis or combinations of both. Most prominently induced cytokines are
highlighted in colored boxes. Quantitation of relative fold induction of
cytokines compared with DMSO control cells were measured. Data are
representative of two independent experiments.
Statistical significance was analyzed
using 2-way ANOVA * p≤0.05, ** p<0.01, *** p
< 0.001, **** p < 0.0001 relative to control.